December 11, 2009 (FinancialWire) — Vical Inc. (NASDAQ: VICL) said that the company is addressing an international gathering of pandemic influenza vaccine experts and potential commercial partners to encourage broader use of the company’s DNA vaccine technology and Vaxfectin(R) adjuvant.

Larry R. Smith, Ph.D., Vical’s vice president of Vaccine Research, presented TODAY at the World Influenza Congress Europe (Brussels — December 7-9), an innovative forum for the discussion of influenza policy and planning, vaccine research and development, and commercialization opportunities.

Dr. Smith’s presentation, “DNA Vaccines: Rapid Response to Pandemic Outbreaks,” highlights the unique advantages of DNA vaccines for threats such as the recent H1N1 swine flu and other emerging diseases. DNA vaccines can be developed and produced very quickly using scaleable manufacturing processes which are not dependent upon chicken eggs or other cell culture methods. They contain no infectious components and do not require any handling of the target pathogen, affording a favorable safety profile. Their inherent stability allows versatile shipping and storage conditions. Their ability to elicit both antibody and T-cell responses offers excellent flexibility and precise matching to the specific vulnerabilities of each pathogen. DNA vaccines can be formulated in simple saline solution, or with Vical’s Vaxfectin(R) adjuvant or other excipients designed to enhance the desired type of immune response.

The presentation also features Vical’s RapidResponse DNA vaccine manufacturing platform, which is designed to significantly reduce the time required to develop, manufacture and deploy vaccines against emerging diseases during the early stages of an infectious outbreak. It is ideally suited to enable an immediate response against emerging diseases affecting large populations, such as pandemic influenza or severe acute respiratory syndrome . The company is developing the RapidResponse platform under a three-year grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and has successfully completed proof-of-concept studies in animals.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.